Cargando…

Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience

The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolpa, Weronika, Zapała, Magdalena, Zwiernik, Bartosz, Mizia-Malarz, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776902/
https://www.ncbi.nlm.nih.gov/pubmed/36553318
http://dx.doi.org/10.3390/children9121874
_version_ 1784855972877959168
author Stolpa, Weronika
Zapała, Magdalena
Zwiernik, Bartosz
Mizia-Malarz, Agnieszka
author_facet Stolpa, Weronika
Zapała, Magdalena
Zwiernik, Bartosz
Mizia-Malarz, Agnieszka
author_sort Stolpa, Weronika
collection PubMed
description The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1–18 years old (median 6.4); female 53.6% vs. male 46.4%. Results: 19 pts (15.2%) were diagnosed with a relapse. Three pts (15.8%) had been diagnosed with very early relapses (2/3 T-ALL), 12 pts (63.1%) as an early relapse, and 4 pts (21.1%) as a late relapse. Bone marrow was the most frequent relapses localization. The five-year survival has been achieved by six patients (31.6%). A significant difference was found in regard to the five-year overall survival and relapse type (p < 0.05). The group with very early relapses (3/3; 100%) has not reached the five-year survival. Conclusions: 1. The main prognostic factor in children’s ALL relapses is still the time of the onset of the relapse. 2. The T lineage acute lymphoblastic leukemia is a worse prognostic factor. 3. The analysis of the above relapse risk factors alongside cytogenethic markers and flow cytometry or polymerase chain reaction minimal residual disease is very important for first-line chemotherapy improvement and a more personalized choice of therapy for ALL patients.
format Online
Article
Text
id pubmed-9776902
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97769022022-12-23 Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience Stolpa, Weronika Zapała, Magdalena Zwiernik, Bartosz Mizia-Malarz, Agnieszka Children (Basel) Article The prognosis in children and adolescents with relapsed ALL, despite intensive therapy, including hematopoietic stem cell transplantation, is still challenging. This study aims to analyze the incidence of relapsed ALL and survival rates in correlation to the risk factors. Materials and methods: 125 pediatric patients with ALL diagnosed in our department between 2000-2018; age 1–18 years old (median 6.4); female 53.6% vs. male 46.4%. Results: 19 pts (15.2%) were diagnosed with a relapse. Three pts (15.8%) had been diagnosed with very early relapses (2/3 T-ALL), 12 pts (63.1%) as an early relapse, and 4 pts (21.1%) as a late relapse. Bone marrow was the most frequent relapses localization. The five-year survival has been achieved by six patients (31.6%). A significant difference was found in regard to the five-year overall survival and relapse type (p < 0.05). The group with very early relapses (3/3; 100%) has not reached the five-year survival. Conclusions: 1. The main prognostic factor in children’s ALL relapses is still the time of the onset of the relapse. 2. The T lineage acute lymphoblastic leukemia is a worse prognostic factor. 3. The analysis of the above relapse risk factors alongside cytogenethic markers and flow cytometry or polymerase chain reaction minimal residual disease is very important for first-line chemotherapy improvement and a more personalized choice of therapy for ALL patients. MDPI 2022-11-30 /pmc/articles/PMC9776902/ /pubmed/36553318 http://dx.doi.org/10.3390/children9121874 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stolpa, Weronika
Zapała, Magdalena
Zwiernik, Bartosz
Mizia-Malarz, Agnieszka
Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
title Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
title_full Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
title_fullStr Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
title_full_unstemmed Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
title_short Relapses Children’s Acute Lymphoblastic Leukemia, Single Center Experience
title_sort relapses children’s acute lymphoblastic leukemia, single center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776902/
https://www.ncbi.nlm.nih.gov/pubmed/36553318
http://dx.doi.org/10.3390/children9121874
work_keys_str_mv AT stolpaweronika relapseschildrensacutelymphoblasticleukemiasinglecenterexperience
AT zapałamagdalena relapseschildrensacutelymphoblasticleukemiasinglecenterexperience
AT zwiernikbartosz relapseschildrensacutelymphoblasticleukemiasinglecenterexperience
AT miziamalarzagnieszka relapseschildrensacutelymphoblasticleukemiasinglecenterexperience